|
Q1 FY2027
As of Jun 30, 2026
|
Q4 FY2026
As of Mar 31, 2026
|
Q3 FY2026
As of Dec 31, 2025
|
Q2 FY2026
As of Sep 30, 2025
|
Q1 FY2026
As of Jun 30, 2025
|
Q4 FY2025
As of Mar 31, 2025
|
Q3 FY2025
As of Dec 31, 2024
|
Q2 FY2025
As of Sep 30, 2024
|
Q1 FY2025
As of Jun 30, 2024
|
Q4 FY2024
As of Mar 31, 2024
|
Q3 FY2024
As of Dec 31, 2023
|
Q2 FY2024
As of Sep 30, 2023
|
Q1 FY2024
As of Jun 30, 2023
|
Q4 FY2023
As of Mar 31, 2023
|
Q3 FY2023
As of Dec 31, 2022
|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Accounts Receivable (net allowance of $0 and $0 respectively) | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Equity securities | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Long lived assets, available for sale | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Non-Current Assets: | ||||||||||||||||||||
| Telemedicine Platform | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right of use assets, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Deferred tax asset, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Total other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Payroll Wages and Taxes Payable | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses and other payable | ||||||||||||||||||||
| Accrued expenses and other payables | ||||||||||||||||||||
| Current portion of operating lease obligations | ||||||||||||||||||||
| Current portion of loans and obligations | ||||||||||||||||||||
| Accrued settlement | ||||||||||||||||||||
| Total accrued settlement | ||||||||||||||||||||
| Other Payables - Equipment Leases | ||||||||||||||||||||
| Interest Payable | ||||||||||||||||||||
| Total interest Payable | ||||||||||||||||||||
| Current portion of loans & obligations | ||||||||||||||||||||
| Short-term business loans | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Long-Term Liabilities: | ||||||||||||||||||||
| Lease liability | ||||||||||||||||||||
| SBA Loans | ||||||||||||||||||||
| Equipment loans and obligations non-current | ||||||||||||||||||||
| Loans and Obligations | ||||||||||||||||||||
| Total Long-Term Liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||
| Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of June 30, 2026, and March 31, 2026, respectively | ||||||||||||||||||||
| Common stock, par value $0.001 per share, 300,000,000 shares authorized; 287,590,881 issued and outstanding, and 291,324,607 issued and outstanding as of June 30, 2026, and March 31, 2026, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Treasury Stock, at cost (0 and 1,045,296 shares as of March 31, 2026, and March 31, 2025, respectively) | ||||||||||||||||||||
| Total Stockholders’ Equity | ||||||||||||||||||||
| Non-Controlling interest (“NCI”) | ||||||||||||||||||||
| Total Equity | ||||||||||||||||||||
| Total Liabilities and Equity | ||||||||||||||||||||
Loading...
